医薬品リファレンス
Ramucirumab
Ramucirumab is a medicine in the class oncology. It is used for colorectal cancer.
- 薬効分類: Oncology
- 効能・効果: colorectal cancer
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FX06
- 一般的な剤形
- 注射剤, 溶液
- 一般的な規格
- 10 mg/ml, 100 mg/10 ml, 500 mg/50 ml
- 既知の相互作用
- 2 (中等度: 2)
- 商品名
- 7
- 国・市場
- 5
何に使われるか
作用のしくみ
Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds VEGF receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells.
成人の通常用量（添付文書の要約）
Non-Small Cell Lung Cancer: Ramucirumab 10 mg/kg IV on Day 1, PLUS Docetaxel 75 mg/m2 IV on Day 1, Repeat cycle every 21 days, Continue until disease progression or unacceptable toxicity.
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: it blocks VEGFR2, which the placenta and fetal blood vessels need (mice lacking VEGFR2 die as embryos); no human or animal reproduction studies. Check pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose.
- 授乳
- Unsafe No human milk data. As a large antibody, milk levels are likely very low and poorly absorbed, but serious infant reactions are possible. Do not breastfeed during treatment and for 2 months after the last dose (US label; LactMed concurs with caution).
報告されている副作用
- Fatigue
- Diarrhea
- Asthenia
- Neutropenia
- Hypertension
- Epistaxis
注意が必要な方
- Impaired wound healing can occur with antibodies inhibiting the VEGF or VEGFR pathway; VEGFR2 antagonist has the potential to adversely affect wound healing
- Withhold for 28 days prior to elective surgery; do not administer for at least 2 weeks following a major surgical procedure and until adequate wound healing
- May cause hypothyroidism; monitor thyroid function during treatment
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (2)
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Ramucirumabの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Ramucirumab used for?
Ramucirumab is a medicine in the class oncology. It is used for Colorectal cancer, Gastric cancer, Hepatocellular carcinoma, Lung cancer.
What side effects have been reported with Ramucirumab?
Fatigue, Diarrhea, Asthenia, Neutropenia, Hypertension, Epistaxis.
Can Ramucirumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: it blocks VEGFR2, which the placenta and fetal blood vessels need (mice lacking VEGFR2 die as embryos); no human or animal reproduction studies. Check pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose. Breastfeeding: Unsafe. No human milk data. As a large antibody, milk levels are likely very low and poorly absorbed, but serious infant reactions are possible. Do not breastfeed during treatment and for 2 months after the last dose (US label; LactMed concurs with caution).
What does Ramucirumab interact with?
MediHelp lists 2 known interactions for Ramucirumab. Moderate: 2. The most serious include Efgartigimod / hyaluronidase sc, Efgartigimod alfa.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
